Table 1.
Individual characteristics and group summary for participants with PD and summary for HOA and HYA groups.
| Age | PD duration | Sex | MDS-UPDRS | H & Y | MoCA | Medications (LED) | |
|---|---|---|---|---|---|---|---|
| PD-101 | 66 | 13 | M | 32 | 2 | 29 | Carbidopa/levodopa, pramipexole (256) |
| PD-102 | 67 | 7 | F | 21 | 2 | 26 | Carbidopa/levodopa, pramipexole, selegiline (204) |
| PD-103 | 77 | 3 | M | 41 | 2 | 27 | Carbidopa/levodopa (63) |
| PD-104 | 62 | 17 | F | 47 | 2 | 26 | Carbidopa/levodopa, entacapone, amantadine, ropinirole (958) |
| PD-105 | 72 | 6 | F | 18 | 3 | 27 | Carbidopa/levodopa, rasagiline (163) |
| PD-106 | 66 | 4 | F | 9 | 1 | 29 | Rasagiline, pramipexole (125) |
| PD-107 | 78 | 9 | M | 31 | 2 | 22 | Carbidopa/levodopa, pramipexole (525) |
| PD-108 | 81 | 2 | M | 46 | 2 | 27 | Carbidopa/levodopa (75) |
| PD-109 | 70 | 7 | M | 57 | 2 | 30 | Carbidopa/levodopa, pramipexole (450) |
| PD-110 | 70 | 8 | F | 18 | 2 | 25 | Carbidopa/levodopa (200) |
| PD-111 | 83 | 4 | M | 22 | 2 | 29 | Carbidopa/levodopa (150) |
| PD-112 | 79 | 6 | M | 49 | 3 | 23 | Carbidopa/levodopa, amantadine (425) |
| PD-113 | 71 | 4 | M | 38 | 2 | 28 | Ropinirole (160) |
| PD-114 | 68 | 1 | M | 25 | 2 | 29 | Selegiline (100) |
| PD-115 | 73 | 1 | F | 23 | 3 | 29 | Carbidopa/levodopa (125) |
|
| |||||||
| PD mean (SD) range |
72.2 (6.2) 62–83 |
6.1 (4.4) | 6 F/9 M | 32 (14) 9–57 |
2.1 (1.5) 1–3 |
27.1 (2.3) 22–30 |
265 (238) |
|
| |||||||
| HOA mean (SD) range |
69.2 (7.1) 60–80 |
— | 10 F/5 M | — | — | 28.5 (1.7) 24–30 |
— |
|
| |||||||
| HYA mean (SD) range |
26.4 (4.3) 20–36 |
— | 9 F/6 M | — | — | — | — |
Age and PD duration in years. MDS-UPDRS: Movement Disorders Society Unified Parkinson's Disease Rating Scale, motor examination. H & Y: Hoehn and Yahr rating scale. MoCA: Montreal Cognitive Assessment. LED: levodopa equivalent dosage. SD: standard deviation.